antibodi
mediat
allograft
reject
increasingli
recogn
problem
clinic
transplant
howev
primari
locat
donor
specif
alloantibodi
dsa
produc
cell
transplant
identifi
purpos
studi
test
contribut
allospecif
antibodi
secret
cell
asc
differ
anatom
compart
mous
transplant
model
fulli
mhcmismatch
heart
allograft
transplant
three
group
recipi
nonsensit
wild
type
alloantigensensit
wild
type
mice
exagger
alloantibodi
respons
found
previou
sensit
donor
alloantigen
result
develop
antidonor
alloantibodi
alloab
acceler
kinet
nevertheless
number
alloantibodi
secret
cell
serum
titer
antidonor
igg
alloantibodi
equival
sensit
nonsensit
recipi
six
week
transplant
regardless
recipi
sensit
statu
spleen
contain
higher
number
donorreact
asc
bone
marrow
day
transplant
furthermor
individu
spleen
asc
produc
antidonor
igg
alloantibodi
bone
marrow
asc
taken
togeth
result
indic
spleen
rather
bone
marrow
major
sourc
donorreact
alloab
earli
transplant
sensit
nonsensit
recipi
despit
advanc
immunosuppress
routin
panel
reactiv
antibodi
screen
prior
transplant
donor
specif
alloantibodi
dsa
mediat
unaccept
high
incid
acut
allograft
reject
contribut
develop
chronic
reject
order
develop
therapi
effect
target
dsa
secret
cell
crucial
understand
cellular
mechan
dsa
product
follow
migrat
bone
marrow
bm
secondari
lymphoid
organ
b
cell
activ
encount
antigen
presenc
prime
helper
cell
extrafollicular
cell
rich
environ
activ
b
cell
either
develop
shortliv
plasma
cell
pc
secret
low
affin
antibodi
enter
germin
center
reaction
driven
special
subset
follicular
helper
cell
prolifer
somat
hypermut
affin
matur
isotyp
switch
germin
center
b
cell
differenti
longliv
pc
memori
b
cell
longliv
pc
either
migrat
back
bm
remain
spleen
lymph
node
nondivid
cell
continu
secret
antibodi
absenc
antigen
increas
antibodi
product
respons
specif
cytokin
contribut
differ
antibodi
secret
cell
asc
subset
maintain
serum
antibodi
level
determin
multipl
factor
antigen
type
dose
site
antigen
administr
antigen
persist
magnitud
initi
inflammatori
respons
current
inform
role
asc
variou
anatom
compart
predominantli
deriv
variou
model
infect
immun
isotypeswitch
asc
detect
lymphoid
organ
drain
infect
site
earli
sever
day
infect
earli
peak
spleen
lymph
node
asc
follow
gradual
declin
antigenspecif
asc
bm
increas
time
typic
reach
plateau
week
infect
coincid
presenc
high
serum
antibodi
titer
therefor
gener
believ
bm
asc
respons
maintain
antivir
serum
antibodi
level
protect
follow
reinfect
addit
antigenspecif
asc
detect
nonlymphoid
tissu
follow
inflamm
thu
infect
central
nervou
system
cn
virusspecif
asc
accumul
within
cn
play
local
protect
role
murin
model
influenza
viral
antigenspecif
acss
within
lung
observ
persist
longer
compar
spleen
chronic
inflamm
also
lead
format
ectop
lymphoid
follicl
contain
longliv
asc
detect
mening
multipl
sclerosi
patient
contrast
extens
character
humor
respons
infect
vaccin
sequenc
event
lead
appear
mainten
donorspecif
alloantibodi
serum
transplant
recipi
less
well
defin
current
concept
alloantibodi
product
transplant
recent
summar
stegal
et
al
particular
due
low
frequenc
alloreact
asc
pauciti
assay
identifi
cell
consider
gap
remain
identifi
locat
alloantibodi
produc
cell
rel
import
recent
demonstr
pcenrich
popul
cell
isol
bm
sensit
renal
allograft
candid
abl
produc
alloantibodi
vitro
specif
ident
alloantibodi
found
serum
howev
remain
difficult
evalu
rel
import
bm
alloantibodi
product
spleen
lymph
node
sampl
gener
avail
human
subject
furthermor
main
sourc
alloreact
antibodi
prior
versu
follow
transplant
could
differ
sensit
recipi
current
studi
use
mous
cardiac
transplant
model
test
whether
contribut
allospecif
asc
differ
anatom
compart
depend
sensit
statu
recipi
time
elaps
transplant
show
regardless
sensit
statu
asc
spleen
graftdrain
lymph
node
rather
bm
main
sourc
donorspecif
alloantibodi
earli
stage
transplant
week
transplant
differ
allospecif
antibodi
product
anatom
compart
becom
less
signific
magnitud
antidonor
humor
respons
affect
initi
sensit
statu
recipi
also
investig
mechan
previous
report
exagger
dsa
product
heart
allograft
recipi
demonstr
mice
possess
antidonor
cell
humor
reactiv
prior
transplant
respons
allograft
similar
sensit
wild
type
wt
recipi
follow
mice
age
week
purchas
jackson
laboratori
bar
harbor
femal
b
k
b
b
ia
b
male
balbc
k
l
ia
ie
male
sjl
k
l
ia
ie
male
background
anim
maintain
bred
pathogenfre
facil
cleveland
clinic
procedur
involv
anim
approv
institut
anim
care
use
committe
cleveland
clinic
vascular
heterotop
cardiac
allograft
place
monitor
previous
describ
reject
defin
loss
palpabl
heartbeat
confirm
laparotomi
gener
allosensit
recipi
femal
mice
subcutan
inject
balbc
splenocyt
complet
freund
adjuv
cfa
prepar
mix
incomplet
freund
adjuv
sigmaaldrich
st
loui
mo
lyophil
tuberculosi
mgml
difco
laboratori
detroit
mi
effici
sensit
monitor
recipi
measur
serum
titer
balbc
reactiv
igg
alloantibodi
immun
balbc
heart
allograft
transplant
sensit
recipi
week
immun
induc
antivir
immun
respons
male
mice
intraperiton
inject
plaqu
form
unit
pfu
mous
hepat
viru
strain
jhmv
design
immunohistochemistri
tissu
fix
acid
methanol
methanol
acet
acid
paraffinembed
section
steam
two
chang
trilogyedta
ph
cell
marqu
hot
spring
ar
hr
endogen
peroxidas
activ
block
incub
h
methanol
nonspecif
protein
interact
block
incub
serumfre
protein
block
dako
corp
carpinteria
ca
slide
incub
dilut
biotinspconjug
affin
purifi
f
fragment
goat
antibodi
fcgamma
mous
igg
jackson
immunoresearch
west
grove
pa
min
room
temperatur
slide
subsequ
incub
minut
avidinbiotinenzym
complex
abc
elit
vector
burlingam
ca
follow
diaminobenzidin
counterstain
hematoxylin
phycoerythrin
pe
conjug
antimous
allophycocyanin
apc
conjug
antimous
fluorescein
isothiocyan
fitc
conjug
annexin
v
purchas
bd
pharmingen
san
diego
ca
cell
freshli
isol
spleen
lymph
node
bone
heart
allograft
recipi
cell
obtain
h
vitro
cultur
stain
indic
reagent
previous
describ
analyz
bd
bioscienc
facscalibur
use
cellquest
softwar
bm
spleen
cell
isol
individu
recipi
time
sacrific
cell
cultur
ml
media
lonza
walkersvil
md
supernat
collect
hour
presenc
donorreact
igg
antibodi
determin
thymocyt
bind
assay
apoptosi
rate
viabil
spleen
bm
cell
evalu
prior
cultur
h
cultur
flow
cytometri
donor
balbc
third
parti
sjl
thymocyt
isol
cell
aliquot
incub
serial
dilut
recipi
serum
nondilut
cell
cultur
supernat
fitcconjug
goat
antimous
igg
peconjug
antimous
fitcconjug
antimous
fitcconjug
antimous
biotinyl
antimous
follow
pestreptavidin
conjug
use
detect
antibodi
dilut
bd
pharmingen
cell
wash
fix
paraformaldehyd
analyz
flow
cytometri
cell
cultur
supernat
result
report
mean
fluoresc
intens
mfi
titer
balbcreact
igg
alloantibodi
serum
calcul
previous
publish
igg
isotyp
mfi
dilut
determin
dilut
return
mfi
level
observ
thymocyt
stain
dilut
serum
divid
two
report
titer
frequenc
igg
secret
donorreact
asc
determin
use
elispot
plu
mous
igg
kit
mabtech
ab
nacka
strand
sweden
briefli
serial
dilut
recipi
cell
isol
spleen
graftdrain
mediastin
lymph
node
bm
cultur
h
rpmi
media
supplement
fetal
bovin
serum
fb
plate
coat
antimous
igg
antibodi
cellswel
either
biotinylatedantiigg
biotinyl
molecul
kindli
provid
dr
cornelia
bergmann
cleveland
clinic
ad
detect
reagent
two
hour
rt
extens
wash
plate
incub
streptavidinalkalin
phosphatas
one
hour
rt
follow
bcipnbt
substrat
detect
jhmvspecif
igg
produc
acss
plate
coat
jhmv
viru
pfuwel
serial
dilut
cell
plate
incub
h
asc
detect
subsequ
incub
biotinyl
rabbit
antimous
igg
southern
biotech
birmingham
al
streptavidinhorseradish
peroxidas
bd
pharmingen
substrat
previous
describ
number
spot
per
well
cumul
spot
size
distribut
analyz
use
immunospot
seri
analyz
cellular
technolog
ltd
shaker
height
oh
result
calcul
total
number
asc
per
compart
bm
size
estim
multipli
number
cell
isol
femur
previous
describ
assay
perform
previous
outlin
use
captur
detect
antimous
antibodi
bd
pharmingen
recipi
spleen
cell
stimul
mitomycin
ctreat
balbc
third
parti
sjl
spleen
cell
result
spot
analyz
use
immunospot
seri
analyz
heart
allograft
surviv
compar
group
kaplanmei
analysi
unless
note
otherwis
data
repres
mean
valu
sd
antibodi
titer
analyz
use
nonparametr
mannwhitney
test
result
analyz
anova
follow
bonferroni
posttest
p
valu
consid
signific
differ
femal
mice
subcutan
inject
balbc
splenocyt
cfa
order
test
effici
specif
alloimmun
perform
follow
experi
first
spleen
cell
sensit
mice
analyz
elispot
enumer
alloantigenspecif
cell
respons
balbc
stimul
significantli
higher
third
parti
stimul
day
declin
baselin
level
day
immun
figur
second
sera
immun
mice
test
presenc
balbcreact
alloantibodi
high
titer
balbc
reactiv
detect
sensit
mice
day
althogh
immun
mice
low
serum
titer
figur
third
number
total
iggproduc
asc
well
asc
secret
specif
igg
evalu
day
immun
elispot
assay
acss
produc
bind
igg
detect
mice
immun
balbc
spleen
cell
led
signific
increas
number
asc
secret
total
bind
igg
spleen
bm
mediastin
lymph
node
figur
consist
sensit
statu
immun
mice
reject
balbc
heart
allograft
acceler
kinet
compar
nonimmun
recipi
mst
day
vs
day
respect
per
group
p
sera
sensit
nonsensit
heart
allograft
recipi
test
develop
donorreact
alloantibodi
antidonor
igg
antibodi
titer
significantli
higher
sensit
nonsensit
recipi
day
transplant
increas
differ
igg
isotyp
figur
donorreact
alloantibodi
titer
remain
stabl
sensit
recipi
day
transplant
gradual
increas
nonsensit
recipi
notabl
day
week
transplant
antidonor
igg
antibodi
titer
compar
group
figur
investig
rel
contribut
spleen
versu
bm
sourc
cell
produc
alloantibodi
spleen
bm
cell
suspens
prepar
heart
allograft
recipi
cultur
vitro
hour
without
restimul
presenc
donorspecif
antibodi
evalu
test
abil
cultur
supernat
bind
donor
thymocyt
bind
mfi
level
spleen
cell
supernat
higher
sensit
nonsensit
group
day
transplant
howev
bind
spleen
cell
supernat
sensit
nonsensit
recipi
compar
week
post
transplant
figur
bind
mfi
significantli
higher
spleen
compar
bm
supernat
sensit
nonsensit
recipi
figur
find
due
inferior
surviv
bm
plasma
cell
vitro
cultur
cell
spleen
bm
demonstr
similar
viabil
apoptot
rate
figur
differ
spleen
bm
cell
supernat
becam
less
promin
week
transplant
investig
whether
differ
alloantibodi
product
anatom
compart
could
explain
rel
frequenc
asc
quantifi
igg
secret
cell
spleen
bm
graftdrain
mediastin
lymph
node
number
total
igg
spot
significantli
higher
spleen
bm
day
transplant
number
spleen
iggsecret
ac
chang
day
transplant
cell
gradual
accumul
bone
marrow
result
compar
number
igg
secret
cell
two
compart
week
post
transplant
figur
compar
nonsensit
mice
recipi
sensit
result
increas
number
iggproduc
asc
within
spleen
drain
lymph
node
earli
transplant
figur
confirm
immunohistochem
stain
recipi
spleen
section
nonsensit
recipi
igg
produc
asc
appear
transit
bridg
channel
periarteriolar
lymphat
sheet
red
pulp
wherea
larg
number
asc
accumul
border
margin
zone
red
pulp
sensit
mice
figur
major
asc
nonsensit
recipi
appear
plasmacyt
characterist
uneven
granular
stain
cytoplasm
contrast
larger
proport
asc
sensit
recipi
uniformli
dens
stain
cytoplasm
consist
morpholog
matur
plasma
cell
figur
inset
next
evalu
frequenc
total
number
donor
mhcreactiv
asc
within
distinct
anatom
compart
sensit
nonsensit
recipi
regardless
recipi
sensit
statu
detect
cell
secret
bind
igg
spleen
bm
day
transplant
howev
frequenc
donorreact
asc
among
cell
total
number
gradual
decreas
spleen
increas
bm
nonsensit
recipi
becam
compar
twp
compart
week
transplant
figur
b
figur
sensit
recipi
demonstr
similar
trend
kinet
asc
accumul
significantli
higher
frequenc
number
alloreact
asc
spleen
day
bm
day
exclud
possibl
assay
bm
asc
lack
sensit
compar
b
cell
respons
heart
allograft
respons
infecti
agent
test
whether
detect
antigenspecif
bm
asc
model
viral
infect
mice
intraperiton
inject
subleth
strain
mous
hepat
viru
jhmv
report
elicit
potent
humor
respons
frequenc
total
number
asc
produc
virusspecif
igg
evalu
elispot
assay
day
week
infect
notabl
frequenc
asc
day
post
infect
detect
limit
contrast
find
allograft
recipi
bm
infect
mice
contain
higher
number
virusspecif
asc
time
point
despit
increas
donorreact
alloantibodi
titer
serum
nonsensit
recipi
day
transplant
observ
similar
number
donorreact
asc
time
point
therefor
compar
abil
individu
asc
secret
bind
igg
analyz
spot
size
distrubut
elispot
assay
bind
spot
size
increas
time
transplant
indic
increas
product
alloreact
antibodi
individu
cell
figur
gener
spleen
asc
sensit
recipi
form
larger
spot
cell
nonsensit
mice
time
point
examin
bm
asc
sensit
result
enhanc
secret
donorreact
alloab
day
wherea
compar
amount
antibodi
produc
cell
sensit
nonsensit
recipi
week
post
transplant
notabl
individu
spleen
asc
produc
bind
antibodi
compar
bm
asc
regardless
recipi
sensit
statu
time
elaps
transplant
figur
previous
shown
mice
defici
chemokin
receptor
enhanc
humor
immun
respons
donor
alloantigen
compar
wt
anim
develop
acut
humor
reject
heart
kidney
allograft
order
investig
underli
mechan
exagger
alloab
product
condit
evalu
paramet
antidonor
humor
immun
respons
heart
allograft
recipi
previou
studi
wt
recipi
reject
balbc
heart
allograft
similar
kinet
mst
day
vs
day
respect
increas
number
donorspecif
secret
cell
present
compar
wt
recipi
consist
previous
report
exagger
helper
activ
absenc
recipi
develop
high
titer
antidonor
igg
antibodi
acceler
kinet
compar
wt
mice
howev
titer
donorreact
alloab
becam
compar
group
day
transplant
figur
number
total
igg
secret
cell
chang
time
transplant
slightli
significantli
elev
compar
wt
recipi
figur
contrast
recipi
contain
significantli
higher
number
bind
igg
secret
cell
spleen
day
figur
similar
find
sensit
wild
type
recipi
averag
bindingspot
size
spleen
larger
day
compar
wt
recipi
later
time
point
abil
individu
cell
secret
donorreact
igg
antibodi
becam
compar
group
figur
taken
togeth
result
indic
despit
absenc
pretranspl
sensit
paramet
humor
alloimmun
respons
allograft
recipi
similar
observ
sensit
wt
mice
past
two
decad
frequenc
kinet
function
paramet
cell
immun
respons
follow
transplant
well
character
howev
analog
studi
humor
alloimmun
hinder
compar
low
frequenc
alloreact
asc
pauciti
assay
identifi
cell
challeng
evalu
differ
anatom
compart
human
transplant
recipi
recent
studi
perri
et
al
success
detect
alloreact
asc
bm
sensit
patient
use
purifi
hla
molecul
target
howev
role
allospecif
asc
secondari
lymphoid
organ
allograft
recipi
previous
address
current
studi
use
three
differ
model
murin
cardiac
allotransplant
compar
contribut
cell
bm
graft
drain
lymph
node
spleen
donorreact
alloantibodi
product
paramet
humor
alloimmun
respons
evalu
variou
time
point
transplant
measur
serum
titer
donorreact
alloantibodi
compar
abil
spleen
bm
cell
secret
antidonor
alloantibodi
cultur
enumer
total
donorantigen
reactiv
asc
variou
compart
modifi
elispot
assay
show
first
time
spleen
rather
bm
major
sourc
alloab
earli
stage
heart
transplant
first
spleen
cell
produc
higher
level
donorreact
alloab
bm
cell
vitro
cultur
second
higher
number
asc
produc
donorreact
igg
detect
within
spleen
compar
bm
third
individu
spleen
asc
secret
antibodi
bm
asc
examin
time
point
previou
studi
viral
infect
immun
demonstr
initi
antigenspecif
antibodi
product
occur
spleen
bm
antigenspecif
asc
rapidli
take
maintain
serum
antibodi
level
antibodi
product
spleen
cell
wane
observ
similar
kinet
distribut
asc
model
viral
infect
figur
contrast
number
donor
antigenspecif
asc
bone
marrow
neglig
low
first
three
week
transplant
number
spleen
bone
marrow
asc
becom
compar
long
high
serum
level
alloantibodi
achiev
differ
igg
isotyp
dynam
asc
distribut
observ
studi
rais
question
longev
asc
spleen
versu
bm
contrast
acut
viral
infect
alloantigen
rapidli
clear
heart
transplant
may
continu
recruit
new
b
cell
respons
stimul
induct
shortliv
pc
spleen
thu
possibl
spleen
acss
mostli
compris
shortliv
pc
asc
migrat
bm
persist
long
time
analog
respons
induc
pathogen
model
antigen
studi
evalu
life
span
antigen
depend
phenotyp
characterist
spleen
versu
bm
asc
follow
transplant
current
ongo
laboratori
clinic
practic
splenectomi
use
preemptiv
treatment
abo
incompat
recipi
patient
high
dsa
level
increas
risk
antibodi
mediat
reject
perform
prior
transplant
splenectomi
may
reduc
b
cell
allorespons
graft
well
decreas
number
plasmablast
matur
pc
interestingli
two
group
recent
report
success
use
splenectomi
treatment
refractori
antibodi
mediat
renal
allograft
reject
small
group
renal
transplant
patient
studi
dsa
abo
antibodi
titer
decreas
splenectom
recipi
resolut
antibodi
mediat
reject
amr
achiev
outcom
consist
find
role
spleen
mainten
dsa
serum
titer
howev
possibl
case
lymph
node
andor
bm
harbor
suffici
number
asc
overcom
benefici
effect
splenectomi
later
time
point
transplant
mediastin
lymph
node
establish
import
site
antigen
drainag
peritoneum
previou
studi
heterotop
cardiac
allograft
demonstr
donor
dendrit
cell
migrat
mediastin
lymph
node
pc
expand
site
within
week
transplant
current
data
indic
mediastin
lymph
node
site
rapid
prolong
product
donor
specif
antibodi
nevertheless
rel
size
mediastin
lymph
node
modest
compar
spleen
versu
cell
number
lymph
node
asc
consist
lower
observ
spleen
figur
suggest
promin
contribut
spleen
gener
mainten
cell
produc
serum
alloantibodi
frequenc
alloantigenspecif
asc
detect
level
nondrain
axillari
brachial
poplit
lymph
node
data
shown
ca
nt
entir
rule
asc
locat
galt
may
also
contribut
alloantibodi
product
transplant
previou
studi
sensit
patient
perri
et
al
estim
frequenc
bm
cell
secret
antibodi
specif
hla
antigen
low
analog
found
bm
cell
secret
igg
antibodi
bind
repres
donor
mhc
class
molecul
extrem
rare
sensit
mice
earlier
stage
transplant
figur
frequenc
asc
bm
significantli
increas
six
week
post
transplant
reach
dynam
spleen
asc
frequenc
exactli
opposit
number
peak
day
post
transplant
steadili
declin
week
six
nonsensit
sensit
recipi
respect
data
indic
sensit
statu
recipi
alter
anatom
distribut
alloreact
asc
spleen
cell
appear
major
contributor
alloreact
antibodi
product
sensit
recipi
well
howev
result
exclud
possibl
bm
asc
contribut
increas
level
earli
antibodi
product
sensit
recipi
bm
cell
appear
secret
donorreact
day
figur
contain
higher
frequenc
total
donor
mhcreactiv
igg
produc
cell
figur
produc
antidonor
igg
figur
addit
sensit
recipi
studi
uniformli
expos
donor
alloantigen
four
week
prior
transplant
contribut
variou
anatom
compart
may
influenc
time
elaps
initi
sensit
andor
strength
prime
stimulu
anticip
previou
sensit
donor
alloantigen
result
acceler
alloreact
antibodi
respons
follow
heart
allograft
placement
immun
donor
cell
induc
high
titer
igg
isotyp
acceler
respons
entir
attribut
presenc
allospecif
antibodi
prior
transplant
number
total
igg
donorreact
igg
secret
cell
sensit
recipi
increas
significantli
day
transplant
compar
pretranspl
level
suggest
rapid
differenti
memori
b
cell
pc
well
robust
secondari
helper
respons
unexpectedli
absenc
immunosuppress
donorreact
antibodi
respons
sensit
nonsensit
recipi
becam
compar
later
stage
transplant
furthermor
find
mice
indic
even
nonsensit
recipi
antidonor
humor
respons
acceler
presenc
higher
frequienc
donorreact
helper
cell
clinic
implic
result
magnitud
de
novo
dsa
product
transplant
recipi
neg
pra
andor
crossmatch
contain
increas
frequenc
donorreact
helper
cell
may
reach
observ
sensit
recipi
summari
studi
identifi
spleen
major
sourc
donorreact
alloab
sensit
nonsensit
recipi
find
contribut
understand
humor
respons
transplant
facilit
futur
therapi
target
develop
persist
asc
produc
donorreact
alloantibodi
heterotop
balbc
heart
transplant
place
nonsensit
mice
sensit
recipi
four
week
immun
balbc
alloantigen
serum
collect
day
six
week
post
transplant
titer
balb
cand
third
partyreact
alloab
determin
cell
bind
assay
titer
third
partyreact
alloab
serum
sampl
result
compar
use
nonparametr
mannwhitney
test
n
mice
per
group
time
point
